secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2026-07-07T21:12:41+00:00
Accession:  0001217234-26-000038
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+
--------------------------------------------------------------------------------

- Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.
- Acquisition of Naveris closed July 1 for $161.8M cash plus up to $100M earnout based on 2026-2027 revenue milestones.
- Naveris' NavDx test is the only Medicare-covered MRD test for HPV+ head/neck and anal cancers; 130K+ tests reported.
- Naveris generated ~$35M revenue in 2025, more than doubling YoY; ADLT reimbursement rate of $1,800 per test.
- Combined estimated U.S. addressable market exceeds $12B across transplant, specialty oncology, and cell therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/0001217234-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/cdna-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001217234-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer